Skip to main content

Advertisement

Log in

Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff

  • CLINICAL TRIAL
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Adjuvant chemotherapy for primary breast cancer is associated with significant side effects. The aims of this study were (1) to compare health-related quality of life (HRQL) in patients undergoing adjuvant chemotherapy to patients not on chemotherapy and (2) to compare these results against a survey investigating health-care professionals’ knowledge of HRQL.

Methods

Patients on adjuvant cyclophosphamide, methotrexate, fluoracil chemotherapy were compared to ‘low-risk’ patients not on chemotherapy (‘control group’). A questionnaire including the EORTC QLQ-C30, the Hospital Anxiety and Depression Scale (HADS), and the DBCG 89 Questionnaire was administered six times during a 2-year period. Forty-six experienced health-care professionals were asked which quality-of-life issues they thought were affected by adjuvant chemotherapy.

Results

After 2 years, 159 of 242 patients on chemotherapy and 148 of 199 patients in the control group were alive and recurrence-free and had completed all questionnaires. Worse HRQL during chemotherapy was seen, as had been previously suggested, for 23 of 30 variables. A number of the health-care professionals had not indicated patients to have these side effects. Several side effects persisted after the chemotherapy.

Conclusions

This study provides the most comprehensive description of HRQL in adjuvant therapy to date. The discrepancy between patients and doctors/nurses suggests that patients have been insufficiently informed about the impact of chemotherapy on quality of life. The results of this study provide a basis for information that can be given to patients, and indicate that the care offered to patients in chemotherapy should seek to prevent, identify, and alleviate a very broad range of problems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  2. Chia S, Bryce C, Gelmon K (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365:1665–1666

    Article  PubMed  CAS  Google Scholar 

  3. van Dam FSAM, Linssen ACG, Engelsman E, van Benthem J, Hanewald GJFP (1980) Life with cytostatic drugs. In: Mouridsen HT, Palshof T (eds) Breast cancer—experimental and clinical aspects. Pergamon, Oxford, pp 229–233

    Google Scholar 

  4. Meyerowitz BE, Watkins IK, Sparks FC (1983) Quality of life for breast cancer patients receiving adjuvant chemotherapy. Am J Nurs 83:232–234

    Article  PubMed  CAS  Google Scholar 

  5. Knobf MT (1986) Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol 4:678–684

    PubMed  CAS  Google Scholar 

  6. Levine MN, Guyatt GH, Gent M, Pauw SD, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, Levin L, Bush H, Abu-Zahra H, Kotalik J (1988) Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798–1810

    PubMed  CAS  Google Scholar 

  7. Hurny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ (1996) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347:1279–1284

    PubMed  CAS  Google Scholar 

  8. Groenvold M (1997) Quality of life in breast cancer adjuvant therapy: validation and pilot testing of a combination of questionnaires. Breast 6:97–107

    Article  Google Scholar 

  9. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8:723–731

    Article  PubMed  CAS  Google Scholar 

  10. Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH (1999) Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18:233–242

    Article  PubMed  CAS  Google Scholar 

  11. Shapiro CL, Recht A (2001) Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997–2008

    Article  PubMed  CAS  Google Scholar 

  12. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, Mackenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658

    PubMed  CAS  Google Scholar 

  13. Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N (2004) Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 86:153–164

    Article  PubMed  Google Scholar 

  14. Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ (2005) Patients’ preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 16:1786–1794

    Article  PubMed  CAS  Google Scholar 

  15. Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A, for the International Breast Cancer Study Group (1998) Quality of life assessment in the adjuvant setting: is it relevant? Recent Results Cancer Res 152:373–389

    Google Scholar 

  16. Danish Breast Cancer Cooperative Group (1989) DBCG-89. Program for treatment and follow-up of patients with primary, operable breast cancer [in Danish]. DBCG Secretariat, Copenhagen

  17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishmann SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  PubMed  CAS  Google Scholar 

  18. Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370

    PubMed  CAS  Google Scholar 

  19. Groenvold M, Fayers PM, Petersen MA, Mouridsen HT (2006) Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:275–284

    Article  PubMed  CAS  Google Scholar 

  20. Ringdal GI, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 2:129–140

    Article  PubMed  CAS  Google Scholar 

  21. Osoba D, Zee B, Pater J, Warr L, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353–364

    Article  PubMed  CAS  Google Scholar 

  22. McLachlan SA, Devins GM, Goodwin PJ (1998) Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 34:510–517

    Article  PubMed  CAS  Google Scholar 

  23. Groenvold M, Klee MC, Sprangers MAG, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient–observer agreement. J Clin Epidemiol 50:441–450

    Article  PubMed  CAS  Google Scholar 

  24. Groenvold M, Bjorner JB, Klee MC, Kreiner S (1995) Test for item bias in a quality of life questionnaire. J Clin Epidemiol 48:805–816

    Article  PubMed  CAS  Google Scholar 

  25. Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organization for Research and Treatment of Cancer, Brussels

  26. Groenvold M, Fayers PM (1998) Testing for differences in multiple quality of life dimensions: generating hypotheses from the experience of hospital staff. Qual Life Res 7:479–486

    Article  PubMed  CAS  Google Scholar 

  27. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650

    Article  PubMed  CAS  Google Scholar 

  28. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701

    PubMed  CAS  Google Scholar 

  29. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493

    Article  PubMed  CAS  Google Scholar 

  30. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146–152

    PubMed  Google Scholar 

  31. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628–4635

    Article  PubMed  CAS  Google Scholar 

  32. Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C (2004) Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer 91:1893–1901

    Article  PubMed  CAS  Google Scholar 

  33. Macquart-Moulin G, Viens P, Bouscary ML, Genre D, Resbeut M, Gravis G, Camerlo J, Maraninchi D, Moatti JP (1997) Discordance between physicians’ estimations and breast cancer patients’ self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer 76:1640–1645

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Supported by the Danish Cancer Society (91-505 and 94 15001).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mogens Groenvold.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Groenvold, M., Fayers, P.M., Petersen, M.A. et al. Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. Breast Cancer Res Treat 103, 185–195 (2007). https://doi.org/10.1007/s10549-006-9365-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9365-y

Keywords

Navigation